DHQZ 36 

DHQZ 36 is a potent inhibitor of retrograde trafficking. DHQZ 36 inhibits Leishmania amazonensis infection in macrophages with an EC₅₀ of 13.63 μM. DHQZ 36 has potent anti-parasite activity^[1].

EC50: 13.63 μM (Leishmania amazonensis)^[1]

With increasing concentrations of DHQZ 36 there is a significant diminution in the size of parasitophorous vacuoles (LPVs), vacuole sizes are reduced by 30% at 50 μM. These parasites also cause a reduction in the number of parasites per macrophage. Significant parasite loss is observed with as low as 5 μM after treatment with DHQZ 36. Parasites are unable to recover growth when treated with DHQZ 36 at concentrations at or above 12.5 μM^[1].
DHQZ 36 causes over 40% reduction in secreted of parasite proteins. DHQZ 36 causes a reversal in Leishmania induced suppression of IL-6 release by infected cells after LPS activation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

384.44

C₂₁H₁₈F₂N₂OS

1542098-94-1

O=C1N(CC2=CC=C(F)C=C2)C(C3=CC=C(CC)S3)NC4=C1C=C(F)C=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Craig E, et al. Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections. PLoS Negl Trop Dis. 2017 May 15;11(5):e0005556.  [Content Brief]